Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
- More Clinical Trial Sites Sharing Information Online: JMACCT
April 16, 2014
- NCVC Establishes Integrated Information Center to Collect Information on Cardiovascular Diseases from Around the Country
April 16, 2014
- APAC Agrees to Aim for Mutual Recognition of New Drug Review Results by 2020
April 15, 2014
- Sales by 24 Member Companies Total 136.8 Billion Yen in 2013, with 12,361 Employees: JCROA
April 15, 2014
- Rattled Confidence, Dubious Eyes on Doctors “Unfortunate”: JMA Veep
April 11, 2014
- Number of CMRs Growing Rapidly in Anticipation of Major New Product Launches: JSCOA
April 11, 2014
- DSP Pres. Tada Likely to Head JPMA, Astellas’ Hatanaka Tipped for Chief Veep
April 10, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
- OPMA Appoints MTPC President Tsuchiya, Three Others as New Vice Chairmen
April 2, 2014
- JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
- Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
- JPMA Reinstates Nihon Pharmaceutical Membership after 1-Year Suspension
March 25, 2014
- GHIT Fund Announces New Grants to Develop Treatments for Tropical Diseases, Novel Tuberculosis Vaccine
March 24, 2014
- JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
- Japanese Drug Makers Conduct MRCTs in More Countries, but Japan Ranks Just 24th as Trial Location: JPMA Survey
March 18, 2014
- JPWA Members to Display Delivery Prices without Tax from October
March 14, 2014
- 3,551 Contract Medical Sales Reps Work in Japan, Up 5.5%: Survey
March 13, 2014
- PhRMA Issues Principles on Investigator-Initiated Studies, Urges Drug Makers Not to Offer Labor
March 12, 2014
- PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…